CoChat
Sign Up
Cited by 105Bone Metabolism and DiseasesBone health and osteoporosis researchSpaceflight effects on biology

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Osteocyte Network; a Negative Regulatory System for Bone Mass Augmented by the Induction of Rankl in Osteoblasts and Sost in Osteocytes at Unloading

Open access
Moriishi, Takeshi, Fukuyama, Ryo, Ito, Masako, Miyazaki, Toshihiro, Maeno, Takafumi, Kawai, Yosuke, Komori, Hisato, Komori, Toshihisa·2012·PLoS ONE
DOI 10.1371/journal.pone.0040143PMC PMC3387151
Open this paper in CoChat — free accountOpen PDF

Abstract

Reduced mechanical stress is a major cause of osteoporosis in the elderly, and the osteocyte network, which comprises a communication system through processes and canaliculi throughout bone, is thought to be a mechanosensor and mechanotransduction system; however, the functions of osteocytes are still controversial and remain to be clarified. Unexpectedly, we found that overexpression of BCL2 in osteoblasts eventually caused osteocyte apoptosis. Osteoblast and osteoclast differentiation were unaffected by BCL2 transgene in vitro. However, the cortical bone mass increased due to enhanced osteoblast function and suppressed osteoclastogenesis at 4 months of age, when the frequency of TUNEL-positive lacunae reached 75%. In the unloaded condition, the trabecular bone mass decreased in both wild-type and BCL2 transgenic mice at 6 weeks of age, while it decreased due to impaired osteoblast function and enhanced osteoclastogenesis in wild-type mice but not in BCL2 transgenic mice at 4 months of age. Rankl and Opg were highly expressed in osteocytes, but Rankl expression in osteoblasts but not in osteocytes was increased at unloading in wild-type mice but not in BCL2 transgenic mice at 4 months of age. Sost was locally induced at unloading in wild-type mice but not in BCL2 transgenic mice, and the dissemination of Sost was severely interrupted in BCL2 transgenic mice, showing the severely impaired osteocyte network. These findings indicate that the osteocyte network is required for the upregulation of Rankl in osteoblasts and Sost in osteocytes in the unloaded condition. These findings suggest that the osteocyte network negatively regulate bone mass by inhibiting osteoblast function and activating osteoclastogenesis, and these functions are augmented in the unloaded condition at least partly through the upregulation of Rankl expression in osteoblasts and that of Sost in osteocytes, although it cannot be excluded that low BCL2 transgene expression in osteoblasts contributed to the enhanced osteoblast function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0040143

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Osteoblast differentiation and osteoclastogenesis in vitro. (A) ALP activity and mineralization. Primary osteoblasts from wild-type and BCL2 transgenic mice were seeded on 48-well plates at a density of 8×104/well and ALP staining and von Kossa staining were performed after culture for 4 days and 8 days, respectively. Sixteen wild-type and 13 BCL2 transgenic newborn mice were used in two independent experiments, and representative data are shown. (B–D) Co-culture of BMMs and primary osteoblasts. BMMs from wild-type mice were co-cultured with primary osteoblasts from wild-type or BCL2 transgenic mice. TRAP staining was performed after 6 days (B), and the number of multinucleated TRAP-positive cells was counted (C). The resorption activity of the osteoclasts was examined by Pit assay (D), and the resorption pits were measured after 6 days (E). Scale bars = 200 µm. Data are the mean ± S.D. of 5–8 mice. Similar results were obtained in two independent experiments and representative data are shown.
Figure 1 Osteoblast differentiation and osteoclastogenesis in vitro. (A) ALP activity and mineralization. Primary osteoblasts from wild-type and BCL2 transgenic mice were seeded on 48-well plates at a density of 8×104/well and ALP staining and von Kossa staining were performed after culture for 4 days and 8 days, respectively. Sixteen wild-type and 13 BCL2 transgenic newborn mice were used in two independent experiments, and representative data are shown. (B–D) Co-culture of BMMs and primary osteoblasts. BMMs from wild-type mice were co-cultured with primary osteoblasts from wild-type or BCL2 transgenic mice. TRAP staining was performed after 6 days (B), and the number of multinucleated TRAP-positive cells was counted (C). The resorption activity of the osteoclasts was examined by Pit assay (D), and the resorption pits were measured after 6 days (E). Scale bars = 200 µm. Data are the mean ± S.D. of 5–8 mice. Similar results were obtained in two independent experiments and representative data are shown.CC BY · PubMed Central
Figure 2 Transgene expression, osteocyte number, and the frequencies of TUNEL-positive lacunae. (A, B) Real-time RT-PCR analyses of the expression of transgene (A) and Col1a1 (B). The expression levels of the transgene and Col1a1 were examined using RNA that had been extracted from the whole femurs at 2 weeks of age [wt, 8 mice; tg, 7 mice] and osteoblast-enriched samples at 5–6 weeks [wt, 13 mice; tg, 11 mice], 10 weeks [wt, 8 mice; tg, 5 mice], and 4 [wt, 3 mice; tg, 9 mice] and 6 [wt, 5 mice; tg, 8 mice] months of age. The values of wild-type mice were defined as 1, and relative levels are shown in A. The value at 4 months of age was defined as 1, and relative levels are shown in B. (C–J) Immunohistochemical analysis. Sections of wild-type mice at 2 weeks of age (C) and BCL2 transgenic mice at 2 weeks (E), 6 weeks (G), and 4 months (I) of age were reacted with anti-BCL2 antibody. Boxed regions in C, E, G, and I are magnified in D, F, H, and J, respectively. The arrows in H indicate immature osteocytes, which expressed the transgene. The lacunae, which were TUNEL-positive and contained cellular debris of dead osteocytes, were non-specifically reacted with anti-BCL2 antibody in BCL2 transgenic mice. Scale bars = 100 µm (C, E, G, I); 10 µm (D, F, H, J). (K) The number of osteocytes in cortical bone. The number of osteocytes was counted in the cortical bone of femurs at 10 weeks [wt, 9 mice; tg, 12 mice] and 4 months [wt, 14 mice; tg, 13 mice] of age. (L and M) Frequencies of TUNEL-positive lacunae in cortical bone (L) and trabecular bone (M). TUNEL-positive lacunae were counted in femurs at 5–6 weeks [wt, 5 mice; tg, 6 mice], 10 weeks [wt, 7 mice; tg, 9 mice], and 4 [wt, 4 mice; tg, 4 mice] and 6 [wt, 4 mice; tg, 7 mice] months of age. The number of TUNEL-positive lacunae was presented as a percentage of the total number of lacunae. In A, B, and K–M, data are presented as the mean ± S.D. *vs. wild-type mice. *P<0.05, **P<0.01, ***P<0.001, #P<0.05, ##P<0.01, $$$P<0.001.
Figure 2 Transgene expression, osteocyte number, and the frequencies of TUNEL-positive lacunae. (A, B) Real-time RT-PCR analyses of the expression of transgene (A) and Col1a1 (B). The expression levels of the transgene and Col1a1 were examined using RNA that had been extracted from the whole femurs at 2 weeks of age [wt, 8 mice; tg, 7 mice] and osteoblast-enriched samples at 5–6 weeks [wt, 13 mice; tg, 11 mice], 10 weeks [wt, 8 mice; tg, 5 mice], and 4 [wt, 3 mice; tg, 9 mice] and 6 [wt, 5 mice; tg, 8 mice] months of age. The values of wild-type mice were defined as 1, and relative levels are shown in A. The value at 4 months of age was defined as 1, and relative levels are shown in B. (C–J) Immunohistochemical analysis. Sections of wild-type mice at 2 weeks of age (C) and BCL2 transgenic mice at 2 weeks (E), 6 weeks (G), and 4 months (I) of age were reacted with anti-BCL2 antibody. Boxed regions in C, E, G, and I are magnified in D, F, H, and J, respectively. The arrows in H indicate immature osteocytes, which expressed the transgene. The lacunae, which were TUNEL-positive and contained cellular debris of dead osteocytes, were non-specifically reacted with anti-BCL2 antibody in BCL2 transgenic mice. Scale bars = 100 µm (C, E, G, I); 10 µm (D, F, H, J). (K) The number of osteocytes in cortical bone. The number of osteocytes was counted in the cortical bone of femurs at 10 weeks [wt, 9 mice; tg, 12 mice] and 4 months [wt, 14 mice; tg, 13 mice] of age. (L and M) Frequencies of TUNEL-positive lacunae in cortical bone (L) and trabecular bone (M). TUNEL-positive lacunae were counted in femurs at 5–6 weeks [wt, 5 mice; tg, 6 mice], 10 weeks [wt, 7 mice; tg, 9 mice], and 4 [wt, 4 mice; tg, 4 mice] and 6 [wt, 4 mice; tg, 7 mice] months of age. The number of TUNEL-positive lacunae was presented as a percentage of the total number of lacunae. In A, B, and K–M, data are presented as the mean ± S.D. *vs. wild-type mice. *P<0.05, **P<0.01, ***P<0.001, #P<0.05, ##P<0.01, $$$P<0.001.CC BY · PubMed Central
Figure 3 Osteocyte apoptosis in cortical bone. H–E (A, B, E–H, K–N) and TUNEL (C, D, I, J, O, P) staining of cortical bone at the diaphyses of femurs of wild-type mice (A, C, E, G, I, K, M, O) and BCL2 transgenic mice (B, D, F, H, J, L, N, P) at 5–6 weeks (A–D), 4 months (E–J), and 8 months of age (K–P). Boxed regions in E, F, K, and L are magnified in G, H, M, and N, respectively. At 8 months of age, osteocytes with a normal appearance are located in the periphery of the cortical bone of BCL2 transgenic mice (L, N). Scale bars = 0.1 mm (A–F, I–L, O, P); 20 µm (G, H, M, N).
Figure 3 Osteocyte apoptosis in cortical bone. H–E (A, B, E–H, K–N) and TUNEL (C, D, I, J, O, P) staining of cortical bone at the diaphyses of femurs of wild-type mice (A, C, E, G, I, K, M, O) and BCL2 transgenic mice (B, D, F, H, J, L, N, P) at 5–6 weeks (A–D), 4 months (E–J), and 8 months of age (K–P). Boxed regions in E, F, K, and L are magnified in G, H, M, and N, respectively. At 8 months of age, osteocytes with a normal appearance are located in the periphery of the cortical bone of BCL2 transgenic mice (L, N). Scale bars = 0.1 mm (A–F, I–L, O, P); 20 µm (G, H, M, N).CC BY · PubMed Central
Figure 4 Micro-CT and bone histomorphometric analyses of cortical bone (A, B) Micro-CT analysis. Micro-CT images of mid-diaphyses of femurs (A) and cortical thickness, total tissue volume, and bone marrow volume (B) in male wild-type mice (wt) and BCL2 transgenic mice (tg) at 10 weeks [wt, 17 mice; tg, 7 mice], 4 months [wt, 14 mice; tg, 10 mice], and 6 months [wt, 6 mice; tg, 6 mice] of age. Data are presented as the mean ± S.D. (C–G) Dynamic histomorphometric analysis of cortical bone at 4 months of age. C and D, Cross-sections from the mid-diaphyses of femurs of male wild-type mice (C) and BCL2 transgenic mice (D), in which calcein had been injected twice. Scale bars = 0.5 mm. E–G, Mineral apposition rate (MAR) (E), double-labeled surface (dLS/BS) (F), and bone formation rate (BFR/BS) (G) in the endosteum (En) and periosteum (Pe) at the mid-diaphyses of femurs of wild-type mice (w, blue) and BCL2 transgenic mice (t, red). Data are the mean ± S.D. of 10 mice. *vs. wild-type mice. *, ♯, $ P<0.05; **, ♯♯ P<0.01; ***, ♯♯♯ P<0.001. (H) Comparison of the serum osteocalcin level in male four wild-type mice and five BCL2 transgenic mice at 4 months of age. Data are presented as the mean ± S.D. *vs. wild-type mice. **P<0.01.
Figure 4 Micro-CT and bone histomorphometric analyses of cortical bone (A, B) Micro-CT analysis. Micro-CT images of mid-diaphyses of femurs (A) and cortical thickness, total tissue volume, and bone marrow volume (B) in male wild-type mice (wt) and BCL2 transgenic mice (tg) at 10 weeks [wt, 17 mice; tg, 7 mice], 4 months [wt, 14 mice; tg, 10 mice], and 6 months [wt, 6 mice; tg, 6 mice] of age. Data are presented as the mean ± S.D. (C–G) Dynamic histomorphometric analysis of cortical bone at 4 months of age. C and D, Cross-sections from the mid-diaphyses of femurs of male wild-type mice (C) and BCL2 transgenic mice (D), in which calcein had been injected twice. Scale bars = 0.5 mm. E–G, Mineral apposition rate (MAR) (E), double-labeled surface (dLS/BS) (F), and bone formation rate (BFR/BS) (G) in the endosteum (En) and periosteum (Pe) at the mid-diaphyses of femurs of wild-type mice (w, blue) and BCL2 transgenic mice (t, red). Data are the mean ± S.D. of 10 mice. *vs. wild-type mice. *, ♯, $ P<0.05; **, ♯♯ P<0.01; ***, ♯♯♯ P<0.001. (H) Comparison of the serum osteocalcin level in male four wild-type mice and five BCL2 transgenic mice at 4 months of age. Data are presented as the mean ± S.D. *vs. wild-type mice. **P<0.01.CC BY · PubMed Central
Figure 5 Increase of osteoid in BCL2 transgenic mice at 4 months of age. Cortical bone (A–D) and trabecular bone (E–H) of femurs in wild-type (A, C, E, G) and BCL2 transgenic (B, D, F, H) mice at 4 months of age. The boxed regions in A, B, E, and F are magnified in C, D, G, and H, respectively. Osteoid was visualized by Goland-Yoshilki method. Scale bars = 50 µm (A, B, E, F); 10 µm (C, D, G, H). (I) Osteoid thickness. Data are presented as the mean ± S.D. *vs. wild-type mice. *P<0.05, **P<0.01. wt, 4 mice; tg, 5 mice.
Figure 5 Increase of osteoid in BCL2 transgenic mice at 4 months of age. Cortical bone (A–D) and trabecular bone (E–H) of femurs in wild-type (A, C, E, G) and BCL2 transgenic (B, D, F, H) mice at 4 months of age. The boxed regions in A, B, E, and F are magnified in C, D, G, and H, respectively. Osteoid was visualized by Goland-Yoshilki method. Scale bars = 50 µm (A, B, E, F); 10 µm (C, D, G, H). (I) Osteoid thickness. Data are presented as the mean ± S.D. *vs. wild-type mice. *P<0.05, **P<0.01. wt, 4 mice; tg, 5 mice.CC BY · PubMed Central
Figure 6 Bone resorption in BCL2 transgenic mice. (A–E) Number of osteoclasts in cortical bone. A–D, Sections of femurs stained with TRAP in male wild-type mice (A, B) and BCL2 transgenic mice (C, D) at 4 months of age. Boxed regions in A and C are magnified in B and D, respectively. Arrows show TRAP-positive cells. Sections were counterstained with hematoxylin. Scale bars = 0.5 mm (A, C); 50 µm (B, D). E, Number of TRAP-positive cells in the endosteum (En) and periosteum (Pe) of femurs of male wild-type mice (blue) and BCL2 transgenic mice (red) at 2 weeks [wt, 4 mice; tg, 5 mice], 5–6 weeks [wt, 3 mice; tg, 4 mice], 10 weeks [wt, 6 mice; tg, 5 mice], and 4 months [wt, 5 mice; tg, 5 mice] of age. Data are presented as the mean ± S.D. (F) Comparison of the serum TRAP5b level in male three wild-type mice and five BCL2 transgenic mice at 4 months of age. Data are presented as the mean ± S.D. *vs. wild-type mice. *P<0.05.
Figure 6 Bone resorption in BCL2 transgenic mice. (A–E) Number of osteoclasts in cortical bone. A–D, Sections of femurs stained with TRAP in male wild-type mice (A, B) and BCL2 transgenic mice (C, D) at 4 months of age. Boxed regions in A and C are magnified in B and D, respectively. Arrows show TRAP-positive cells. Sections were counterstained with hematoxylin. Scale bars = 0.5 mm (A, C); 50 µm (B, D). E, Number of TRAP-positive cells in the endosteum (En) and periosteum (Pe) of femurs of male wild-type mice (blue) and BCL2 transgenic mice (red) at 2 weeks [wt, 4 mice; tg, 5 mice], 5–6 weeks [wt, 3 mice; tg, 4 mice], 10 weeks [wt, 6 mice; tg, 5 mice], and 4 months [wt, 5 mice; tg, 5 mice] of age. Data are presented as the mean ± S.D. (F) Comparison of the serum TRAP5b level in male three wild-type mice and five BCL2 transgenic mice at 4 months of age. Data are presented as the mean ± S.D. *vs. wild-type mice. *P<0.05.CC BY · PubMed Central
Figure 7 Micro-CT, bone histomorphometry, and real-time RT-PCR analyses after unloading at 4 months of age. (A, B) Micro-CT analysis. Tail suspension was performed for 2 weeks using male wild-type mice [control group, 13 mice; unloaded group, 9 mice] and BCL2 transgenic mice [control group, 8 mice; unloaded group, 8 mice] at 4 months of age. A, Micro-CT images of femurs. Scale bars = 0.5 mm. B, Trabecular bone volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were evaluated by micro-CT. (C) Bone histomorphometrical analysis of trabecular bone. The trabecular bone volume (BV/TV), osteoid thickness (O.Th), number of osteoblasts (N.Ob/B.Pm), number of osteoclasts (N.Oc/B.Pm), eroded surface (ES/BS), mineral apposition rate (MAR), double-labeled surface (dLS/BS), and bone formation rate (BFR/BS) were measured on distal femoral metaphysis in wild-type mice [control group, 8 mice; unloaded group, 11 mice] and BCL2 transgenic mice [control group, 8 mice; unloaded group, 6 mice] at 4 months of age. (D) Ctsk expression. Tail suspension was performed for 3 days and Ctsk expression was examined by real-time RT-PCR analysis using osteoblast-enriched samples from wild-type mice [control group, 9 mice; unloaded group, 11 mice] and BCL2 transgenic mice [control group, 6 mice; unloaded group, 5 mice] at 4 months of age. The values of the control groups were defined as 1, and relative levels are shown. In B–D, data are presented as the mean ± S.D. *vs. control. *, ♯ P<0.05; **, ♯♯ P<0.01.
Figure 7 Micro-CT, bone histomorphometry, and real-time RT-PCR analyses after unloading at 4 months of age. (A, B) Micro-CT analysis. Tail suspension was performed for 2 weeks using male wild-type mice [control group, 13 mice; unloaded group, 9 mice] and BCL2 transgenic mice [control group, 8 mice; unloaded group, 8 mice] at 4 months of age. A, Micro-CT images of femurs. Scale bars = 0.5 mm. B, Trabecular bone volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were evaluated by micro-CT. (C) Bone histomorphometrical analysis of trabecular bone. The trabecular bone volume (BV/TV), osteoid thickness (O.Th), number of osteoblasts (N.Ob/B.Pm), number of osteoclasts (N.Oc/B.Pm), eroded surface (ES/BS), mineral apposition rate (MAR), double-labeled surface (dLS/BS), and bone formation rate (BFR/BS) were measured on distal femoral metaphysis in wild-type mice [control group, 8 mice; unloaded group, 11 mice] and BCL2 transgenic mice [control group, 8 mice; unloaded group, 6 mice] at 4 months of age. (D) Ctsk expression. Tail suspension was performed for 3 days and Ctsk expression was examined by real-time RT-PCR analysis using osteoblast-enriched samples from wild-type mice [control group, 9 mice; unloaded group, 11 mice] and BCL2 transgenic mice [control group, 6 mice; unloaded group, 5 mice] at 4 months of age. The values of the control groups were defined as 1, and relative levels are shown. In B–D, data are presented as the mean ± S.D. *vs. control. *, ♯ P<0.05; **, ♯♯ P<0.01.CC BY · PubMed Central
Figure 8 Real-time RT-PCR analyses of the expression of osteocyte and osteoblast marker genes, Rankl, Opg, and Wnt antagonist genes at 4 months of age. (A) Expression of Dmp1, Sost, Phex, Fgf23, and Mepe in the osteoblast fractions (OB, n = 6) and osteocyte fractions (OC, n = 9) of wild-type mice. The values of osteoblast fractions were defined as 1, and relative levels are shown. *vs. osteoblast fractions. (B) Expression of Dmp1, Sost, Phex, Fgf23, and Mepe in control groups of wild-type mice (n = 4) and BCL2 transgenic mice (n = 5). The values of wild-type mice were defined as 1, and relative levels are shown. (C) Expression of osteoblast marker genes. Expressions of keratocan (Kera), Runx2, Osterix, Col1a1, and osteocalcin (OCN) were examined by real-time RT-PCR using osteoblast-enriched samples and osteocyte-enriched samples from 7 wild-type mice at 6 weeks of age. The values of osteocyte fractions were defined as 1, and relative levels are shown. *vs. osteocyte fractions. (D) Rankl and Opg expression in osteoblast-enriched samples after unloading. Tail suspension was performed for 3 days using male wild-type mice [control group, 8 mice; unloaded group, 9 mice] and BCL2 transgenic mice [control group, 12 mice; unloaded group, 6 mice] at 4 months of age. (E) Expression of Rankl and Opg in the osteoblast fractions (OB) and osteocyte fractions (OC) from 6 and 11 wild-type mice at 4 months of age, respectively. The values of osteoblast fractions were defined as 1, and relative levels are shown. *vs. osteoblast fractions. (F) Expression of Rankl and Opg in osteocyte-enriched samples. Tail suspension was performed for 3 days using male wild-type mice [control group, 9 mice; unloaded group, 8 mice] and BCL2 transgenic mice [control group, 12 mice; unloaded group, 11 mice] at 4 months of age. (G) Expression of Wnt antagonist genes in osteocyte-enriched samples after unloading. Tail suspension was performed for 3 days using male wild-type mice and BCL2 transgenic mice at 4 months of age (8 mice in each group). The values of the control group of wild-type mice were defined as 1, and relative levels are shown in D, F, and G. In A–G, data are presented as the mean ± S.D. *vs. control in D, F, and G. *, ♯ P<0.05; **P<0.01; ***P<0.001.
Figure 8 Real-time RT-PCR analyses of the expression of osteocyte and osteoblast marker genes, Rankl, Opg, and Wnt antagonist genes at 4 months of age. (A) Expression of Dmp1, Sost, Phex, Fgf23, and Mepe in the osteoblast fractions (OB, n = 6) and osteocyte fractions (OC, n = 9) of wild-type mice. The values of osteoblast fractions were defined as 1, and relative levels are shown. *vs. osteoblast fractions. (B) Expression of Dmp1, Sost, Phex, Fgf23, and Mepe in control groups of wild-type mice (n = 4) and BCL2 transgenic mice (n = 5). The values of wild-type mice were defined as 1, and relative levels are shown. (C) Expression of osteoblast marker genes. Expressions of keratocan (Kera), Runx2, Osterix, Col1a1, and osteocalcin (OCN) were examined by real-time RT-PCR using osteoblast-enriched samples and osteocyte-enriched samples from 7 wild-type mice at 6 weeks of age. The values of osteocyte fractions were defined as 1, and relative levels are shown. *vs. osteocyte fractions. (D) Rankl and Opg expression in osteoblast-enriched samples after unloading. Tail suspension was performed for 3 days using male wild-type mice [control group, 8 mice; unloaded group, 9 mice] and BCL2 transgenic mice [control group, 12 mice; unloaded group, 6 mice] at 4 months of age. (E) Expression of Rankl and Opg in the osteoblast fractions (OB) and osteocyte fractions (OC) from 6 and 11 wild-type mice at 4 months of age, respectively. The values of osteoblast fractions were defined as 1, and relative levels are shown. *vs. osteoblast fractions. (F) Expression of Rankl and Opg in osteocyte-enriched samples. Tail suspension was performed for 3 days using male wild-type mice [control group, 9 mice; unloaded group, 8 mice] and BCL2 transgenic mice [control group, 12 mice; unloaded group, 11 mice] at 4 months of age. (G) Expression of Wnt antagonist genes in osteocyte-enriched samples after unloading. Tail suspension was performed for 3 days using male wild-type mice and BCL2 transgenic mice at 4 months of age (8 mice in each group). The values of the control group of wild-type mice were defined as 1, and relative levels are shown in D, F, and G. In A–G, data are presented as the mean ± S.D. *vs. control in D, F, and G. *, ♯ P<0.05; **P<0.01; ***P<0.001.CC BY · PubMed Central
Figure 9 Immunohistochemical analysis of Sost after unloading. Immunohistochemistry using anti-Sost antibody in tibial sections of control (A, B, E, F) and unloaded (C, D, G–J) groups in wild-type (A, C, E, G, I) and BCL2 transgenic (B, D, F, H, J) mice at 4 months of age. The boxed regions with asterisks in A–D are magnified in E–G, respectively. The boxed regions in G and H are magnified in I and J, respectively. In F and H, closed arrows indicate Sost-positive osteocytes and open arrows indicate Sost-negative osteocytes. The lacunae with cellular debris in BCL2 transgenic mice were non-specifically stained with Sost antibody (F, H). The sections were counterstained with methylgreen. Note that Sost is distributed through canaliculi throughout bone in wild-type mice but not in BCL2 transgenic mice (I, J). Scale bars = 0.5 mm (A–D); 50 µm (E–H); 10 µm (I, J). (K–N) Frequency of Sost-positive cells in cortical bone. Sost-positive cells were counted in the anterior (K, M) and posterior (L, N) sides of cortical bone at the metaphysis (K, L) and mid-diaphysis (M, N) of tibiae. Tail suspension was performed for 14 days using male wild-type mice [control group, 7 mice; unloaded group, 9 mice] and BCL2 transgenic mice [control group, 9 mice; unloaded group, 8 mice] at 4 months of age. The number of Sost-positive osteocytes was presented as a percentage of the total number of osteocytes. Only the cells with a nucleus were counted. Data are presented as the mean ± S.D. *vs. control. **P<0.01. (O) Western blot analysis using anti-β-catenin antibody. Proteins were extracted from osteoblast fractions from wild-type and BCL2 transgenic mice at 4 months of age. β-actin was used as an internal control.
Figure 9 Immunohistochemical analysis of Sost after unloading. Immunohistochemistry using anti-Sost antibody in tibial sections of control (A, B, E, F) and unloaded (C, D, G–J) groups in wild-type (A, C, E, G, I) and BCL2 transgenic (B, D, F, H, J) mice at 4 months of age. The boxed regions with asterisks in A–D are magnified in E–G, respectively. The boxed regions in G and H are magnified in I and J, respectively. In F and H, closed arrows indicate Sost-positive osteocytes and open arrows indicate Sost-negative osteocytes. The lacunae with cellular debris in BCL2 transgenic mice were non-specifically stained with Sost antibody (F, H). The sections were counterstained with methylgreen. Note that Sost is distributed through canaliculi throughout bone in wild-type mice but not in BCL2 transgenic mice (I, J). Scale bars = 0.5 mm (A–D); 50 µm (E–H); 10 µm (I, J). (K–N) Frequency of Sost-positive cells in cortical bone. Sost-positive cells were counted in the anterior (K, M) and posterior (L, N) sides of cortical bone at the metaphysis (K, L) and mid-diaphysis (M, N) of tibiae. Tail suspension was performed for 14 days using male wild-type mice [control group, 7 mice; unloaded group, 9 mice] and BCL2 transgenic mice [control group, 9 mice; unloaded group, 8 mice] at 4 months of age. The number of Sost-positive osteocytes was presented as a percentage of the total number of osteocytes. Only the cells with a nucleus were counted. Data are presented as the mean ± S.D. *vs. control. **P<0.01. (O) Western blot analysis using anti-β-catenin antibody. Proteins were extracted from osteoblast fractions from wild-type and BCL2 transgenic mice at 4 months of age. β-actin was used as an internal control.CC BY · PubMed Central
Figure 10 Real-time RT-PCR and micro-CT analyses at 6 weeks of age. (A) Real-time RT-PCR analysis of osteocyte marker genes. RNA was extracted from osteocyte-enriched samples of control groups of wild-type mice and BCL2 transgenic mice at 6 weeks of age. The values of wild-type mice were defined as 1, and relative levels are shown. Data are presented as the mean ± S.D. of 3 mice. *vs. control. *P<0.05. (B, C) Micro-CT analysis of femurs. Tail suspension was performed for 1 week using male wild-type mice [control group, 10 mice; unloaded group, 8 mice] and BCL2 transgenic mice [control group, 9 mice; unloaded group, 6 mice] at 6 weeks of age. B, Micro-CT images. Scale bars = 0.5 mm. C, Trabecular bone volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were evaluated by micro-CT. Data are presented as the mean ± S.D. *vs. control. *,♯P<0.05, **,♯♯P<0.01. (D, E) Real-time RT-PCR analysis after unloading. Tail suspension was performed for 3 days or 7 days using male wild-type mice [control group, 4 mice; unloaded group, 5 mice] and BCL2 transgenic mice [control group, 4 mice; unloaded group, 4 mice] at 6 weeks of age, and RNA was extracted from osteoblast-enriched samples (D) and osteocyte-enriched samples (E) of the tibiae and femurs. The values of the control group of wild-type mice were defined as 1, and relative levels are shown. Data are presented as the mean ± S.D. *vs. control. *P<0.05, **P<0.01.
Figure 10 Real-time RT-PCR and micro-CT analyses at 6 weeks of age. (A) Real-time RT-PCR analysis of osteocyte marker genes. RNA was extracted from osteocyte-enriched samples of control groups of wild-type mice and BCL2 transgenic mice at 6 weeks of age. The values of wild-type mice were defined as 1, and relative levels are shown. Data are presented as the mean ± S.D. of 3 mice. *vs. control. *P<0.05. (B, C) Micro-CT analysis of femurs. Tail suspension was performed for 1 week using male wild-type mice [control group, 10 mice; unloaded group, 8 mice] and BCL2 transgenic mice [control group, 9 mice; unloaded group, 6 mice] at 6 weeks of age. B, Micro-CT images. Scale bars = 0.5 mm. C, Trabecular bone volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th) were evaluated by micro-CT. Data are presented as the mean ± S.D. *vs. control. *,♯P<0.05, **,♯♯P<0.01. (D, E) Real-time RT-PCR analysis after unloading. Tail suspension was performed for 3 days or 7 days using male wild-type mice [control group, 4 mice; unloaded group, 5 mice] and BCL2 transgenic mice [control group, 4 mice; unloaded group, 4 mice] at 6 weeks of age, and RNA was extracted from osteoblast-enriched samples (D) and osteocyte-enriched samples (E) of the tibiae and femurs. The values of the control group of wild-type mice were defined as 1, and relative levels are shown. Data are presented as the mean ± S.D. *vs. control. *P<0.05, **P<0.01.CC BY · PubMed Central
Figure 11 A model of osteocyte functions. (A) In the loaded (physiological) condition, the osteocyte network inhibits osteoblast function, enhances osteoclastogenesis, and negatively regulates bone mass. (B) In the unloaded condition, the effect of osteocyte network on osteoblast function is augmented through the induction of Sost in osteocytes and that on osteoclastogenesis is augmented through the induction of Rankl in osteoblasts, resulting in reduced bone mass. The thickness of the lines and arrows in A and B reflects the strength of the effects.
Figure 11 A model of osteocyte functions. (A) In the loaded (physiological) condition, the osteocyte network inhibits osteoblast function, enhances osteoclastogenesis, and negatively regulates bone mass. (B) In the unloaded condition, the effect of osteocyte network on osteoblast function is augmented through the induction of Sost in osteocytes and that on osteoclastogenesis is augmented through the induction of Rankl in osteoblasts, resulting in reduced bone mass. The thickness of the lines and arrows in A and B reflects the strength of the effects.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Research works printed but not linked: 5

  1. J Xiong, 2011, Matrix-embedded cells control osteoclast formation., Nat Med, 17, 1235, 10.1038/nm.2448 · DOI · Paper page
  2. KE Poole, 2005, Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation., FASEB J, 19, 1842, 10.1096/fj.05-4221fje · DOI · Paper page
  3. X Li, 2005, Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling., J Biol Chem, 280, 19883, 10.1074/jbc.M413274200 · DOI · Paper page
  4. M Semenov, 2005, SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor., J Biol Chem, 280, 26770, 10.1074/jbc.M504308200 · DOI · Paper page
  5. X Li, 2008, Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength., J Bone Miner Res, 23, 860, 10.1359/jbmr.080216 · DOI

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Moriishi, T., Fukuyama, R., Ito, M., Miyazaki, T., Maeno, T., Kawai, Y., Komori, H., & Komori, T.
Affiliations
  • Nagasaki University (JP)
  • Hiroshima International University (JP)
  • Osaka City University (JP)
Corresponding author
Komori, Toshihisa
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2012-06-29
Volume
7
Issue
6
Pages
e40143
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0040143
PMC
PMC3387151
OpenAlex
W1964279564
Cited by
105
References
55
Citations by year
2026: 2 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 7 · 2021: 13 · 2020: 9 · 2019: 6 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 12 · 2014: 11 · 2013: 6
FWCI
3.72
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (publishedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Nagasaki University's Academic Output SITE (Nagasaki University) (submittedVersion, cc-by-nc-nd)
Funders
  • Nakatomi Foundation
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science (24659829, 22249062)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Physiology (medical) › Spaceflight effects on biology
Keywords
osteocyte network, osteocyte apoptosis, Bcl-2, osteoblast activity, osteoclastogenesis, RANKL, sclerostin, osteoporosis, mechanical unloading, mechanotransduction, bone mass regulation, trabecular bone, cortical bone
MeSH terms
Animals, Bone and Bones, Bone Resorption, Cell Count, Cell Differentiation, Glycoproteins, Humans, Immunohistochemistry, Mice, Transgenic, Models, Biological, Organ Size, Osteoblasts, Osteocytes, Osteogenesis, Up-Regulation, Apoptosis, Transgenes, Proto-Oncogene Proteins c-bcl-2, Hindlimb Suspension, Reverse Transcriptase Polymerase Chain Reaction, In Situ Nick-End Labeling, Intercellular Signaling Peptides and Proteins, Adaptor Proteins, Signal Transducing, Mice, RANK Ligand, X-Ray Microtomography, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review